Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141
机构:[1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.[2]Department of Gynecologic, Yunnan Cancer Hospital, Kunming, China.[3]Department of Gynecologic Oncology, Shandong Cancer Hospital, Jinan, China.[4]Department of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.[5]Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China.[6]Department of Tumor Radiotherapy and Chemotherapy, West China Second University Hospital of Sichuan University, Chengdu, China.[7]Department of Gynecologic, Guangxi Cancer Institute, Nanning, China.[8]Department of Gynecologic Oncology, Liaoning Cancer Hospital, Shenyang, China.[9]Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China.[10]The Gynecologic Oncology Center, Peking Union Medical College Hospital, Beijing, China.[11]Department of Gynecologic, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
第一作者机构:[1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
推荐引用方式(GB/T 7714):
Li Rong,Zhang Hongping,Li Qingshui,et al.Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141[J].Journal Of The National Cancer Center.2025,5(1):93-93.doi:10.1016/j.jncc.2024.11.002.
APA:
Li Rong,Zhang Hongping,Li Qingshui,Yuan Guangwen,Zhou Yanjie...&Zhou Qi.(2025).Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141.Journal Of The National Cancer Center,5,(1)
MLA:
Li Rong,et al."Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141".Journal Of The National Cancer Center 5..1(2025):93-93